Detalhe da pesquisa
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068901
2.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582092
3.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 205(3): 589-598, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456970
4.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587643
5.
Anti-Anisakis antibodies in colon cancer patients and their relationship with γδ T-cells.
Parasitol Res
; 123(4): 196, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662084
6.
Top advances of the year: Breast cancer.
Cancer
; 129(12): 1791-1794, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014257
7.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239405
8.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300423
9.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019819
10.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Br J Cancer
; 124(9): 1581-1591, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723394
11.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152285
12.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838010
13.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969184
14.
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Cancer
; 126(4): 894-907, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31714594
15.
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
Gynecol Oncol
; 159(3): 721-731, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988624
16.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796073
17.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol
; 18(4): 545-554, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238593
18.
Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.
Int J Gynecol Cancer
; 2016 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27258723
19.
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Breast Cancer Res Treat
; 154(2): 351-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26536871
20.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
BMC Med
; 17(1): 8, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30621698